Kroger Expands Access to Multi-Dose GLP-1 Therapy with Zepbound KwikPen

Kroger announced today that it will offer the Zepbound® KwikPen, the newly launched multi-dose delivery system for Eli Lilly’s blockbuster weight-management drug, at participating pharmacies.¹ The move aims to improve convenience and reduce barriers for patients seeking glucagon-like peptide-1 (GLP-1) therapies through retail pharmacy locations.

Kroger’s rollout marks a significant shift in how patients can access this specific form of the drug. While Eli Lilly initially launched the Zepbound KwikPen through its direct-to-consumer platform, LillyDirect, in late February 2026, Kroger’s announcement expands availability into the traditional retail pharmacy setting.² A key component of this expansion is the integration of manufacturer-sponsored savings programs designed to reduce out-of-pocket costs for eligible patients.

According to Kroger, for the first time self-pay patients filling prescriptions at retail pharmacies may be eligible for Lilly’s KwikPen Self-Pay Savings Card for Zepbound.¹ The program is intended to lower costs for individuals whose insurance coverage may not include the therapy. Kroger pharmacy associates will also assist patients in navigating insurance benefits, manufacturer savings programs, and other payment pathways to identify the most cost-effective options.¹

“Our customers and communities want affordable, effective weight-management treatment options with real affordability,” said Colleen Lindholz, group vice president and president of Kroger Health, in a press release.¹ “Zepbound KwikPen is now accessible to patients at participating Kroger retail pharmacies, and for the first time this product is available to self-pay patients eligible for Lilly's savings program at a retail pharmacy location.”¹

What is the technology behind the Zepbound KwikPen?

The Zepbound KwikPen represents a technological evolution in the delivery of tirzepatide, the active ingredient in Zepbound. Approved by the FDA through a label expansion, the KwikPen is a multi-dose device that contains four weekly doses of the medication in a single unit.²

Before this launch, patients typically utilized single-dose auto-injectors, requiring four separate devices each month, or single-dose vials that required the manual use of a syringe for self-injection. The KwikPen is intended to serve as a more convenient option, streamlining the injection process and reducing the number of medical devices a patient must manage monthly.² Although new to the Zepbound brand, the KwikPen technology has been utilized globally and within the United States for other Eli Lilly products, most notably the diabetes medication Mounjaro.²

Initial pricing for the KwikPen at the lowest dose level was set at approximately $299 per month for cash−paying patients on the Lilly Direct platform.² This pricing strategy comes as Eli Lilly seeks to maintain its dominant position in the weight−loss market, where Zepbound has seen explosive growth since its late 2023 debut. In the fourth quarter of the previous year, Zepbound generated $4.2 billion in U.S. revenue, representing a 122% increase over the prior year and helping Lilly capture a large share of the market from competitors like Novo Nordisk.²

How Will Kroger Support Patients on GLP-1 Therapies?

Beyond providing the physical medication, Kroger announced it is leveraging its retail footprint to offer a holistic health model for patients on GLP-1 therapies. Recognizing that weight management often requires more than just pharmaceutical intervention, Kroger is integrating several support services:

• Pharmacist Counseling: Personalized guidance on how GLP-1 medications function and strategies for managing potential side effects.
• Virtual Nutrition Care: Access to registered dietitians who can help patients create sustainable, individualized nutrition plans.
• Clinical Continuity: Pharmacy teams are connected with "The Little Clinic" locations to ensure a seamless care journey between providers and pharmacists.
• Nutritional Access: Kroger highlights its unique position as a grocery retailer, allowing patients to fill prescriptions while simultaneously purchasing the protein- and fiber-rich foods necessary to support their health goals.¹

As obesity treatments continue to see high demand, the availability of multi-dose options like the KwikPen at major retail chains may play a pivotal role in long-term patient adherence and health outcomes. Patients interested in the Zepbound KwikPen must provide a valid prescription from a licensed healthcare provider, and availability may vary by location.

References

1. The Kroger Co. Kroger Brings Zepbound® KwikPen to Retail Pharmacy, Expanding Access and Savings for Self-Pay Patients. PR Newswire. March 13, 2026. Accessed March 13, 2026. https://www.prnewswire.com/news-releases/kroger-brings-zepbound-kwikpen-to-retail-pharmacy-expanding-access-and-savings-for-self-pay-patients-302713400.html
2. Constantino AK. Eli Lilly Launches New Form of Obesity Drug Zepbound With a Month’s Worth of Doses in One Pen. CNBC. February 23, 2026. Updated February 24, 2026. Accessed March 13, 2026. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html